Study of CC312 for moderate to severe lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have been diagnosed with lupus (SLE) using the 2019 EULAR/ACR criteria.
- Your lupus is active (SLEDAI-2K score of 7 or more) with at least one severe or two moderate organ flares.
- You have tried at least two standard lupus treatments (like steroids, hydroxychloroquine, or stronger drugs) and they did not work well enough.
- You are willing to use effective birth control during the study and for 6 months after the last dose if you or your partner could get pregnant.
- You do not have severe kidney problems, other autoimmune diseases, active infections, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study tests an investigational drug called ACE1831 for people with active systemic lupus erythematosus (lupus) whose disease has not improved with usual treatments. The goal is to see if ACE1831 can reduce lupus activity and help control symptoms.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.